News

June 11, 2019

Family Friendly Research Poster Session Presenters Announced

Family Friendly Research Poster Session Presenters Announced

The Family Friendly Research Poster Session will be held on Saturday, June 29th from 6:30pm to 8:00pm at the 2019 Annual SMA Conference. 

The Family Friendly Research Poster Session allows for one-on-one interactions between families and researchers. Cure SMA has invited...

READ MORE   |  

Topics: Conference, Research, Front Page News

June 6, 2019

Biogen Issues Q2 Community Statement on Spinraza

Biogen Issues Q2 Community Statement on Spinraza

Dear members of the SMA community,

We are grateful for the opportunity to continue to help support individuals with spinal muscular atrophy (SMA), their caregivers and families. We deeply appreciate our shared goals and are dedicated to helping people with SMA, of all ages, and welcome...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

June 4, 2019

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

Scholar Rock today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 24, 2019

AveXis and Cure SMA to Co-Host Webinar on the FDA's Approval of Zolgensma

On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA approval of Zolgensma. This webinar will include information about the approval, dosing sites, future IT clinical trials, and more. The webinar will also include...

READ MORE   |  

Topics: Research, Front Page News

May 24, 2019

AveXis Issues Community Statement on Zolgensma Approval

AveXis Issues Community Statement on Zolgensma Approval

Dear SMA Community,

We have exciting news to share with you — a major milestone has been reached in the fight against spinal muscular atrophy (SMA)! The US Food and Drug Administration (FDA) has approved ZOLGENSMA® (onasemnogene abeparvovec-xioi) for the treatment of children...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 24, 2019

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis, Inc., a Novartis company, today announced that they have received FDA approval for Zolgensma (formerly AVXS-101), a gene therapy that replaces the survival motor neuron 1 (SMN1) gene,...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 21, 2019

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Audrey Lewis founded Families of SMA, now Cure SMA, 34 years ago. Audrey recognized early on the importance of attracting new and talented researchers to SMA, with the hope that they would commit their careers to developing a treatment and cure for SMA.

Cure SMA honors Audrey’s...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

May 17, 2019

Cure SMA Attends the 71st Annual American Academy of Neurology (AAN) Meeting in Philadelphia

The American Academy of Neurology (AAN) 2019 Annual meeting wrapped up in Philadelphia, Pennsylvania on May 10th, 2019. The AAN Annual meeting is one of the world’s largest professional meeting of neurologists on cutting-edge science, research, and clinical updates. Over 14,000 neurology professionals and meeting attendees were in...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

May 16, 2019

Novartis Issues Community Statement on Branaplam Clinical Study

Novartis Issues Community Statement on Branaplam Clinical Study

Dear SMA Community,

We are writing to inform you that enrollment to the ongoing branaplam clinical study is now closed.

Branaplam is currently being assessed for safety and efficacy in a Phase 1/2 clinical study in Type 1 infantile-onset SMA. We are pleased to announce...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 15, 2019

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

Biogen Inc. today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA...

READ MORE   |  

Topics: Research, Front Page News

Items 1 - 10 of 275  12345678910Next

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software